According to Zacks, “Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. Recro Pharma, Inc. is based in Malvern, Pennsylvania. “
REPH has been the subject of several other research reports. Oppenheimer raised their target price on Recro Pharma from $9.00 to $15.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. ValuEngine raised Recro Pharma from a “hold” rating to a “buy” rating in a research note on Friday, May 24th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $11.30.
Recro Pharma (NASDAQ:REPH) last announced its earnings results on Friday, May 10th. The specialty pharmaceutical company reported ($0.10) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.79) by $0.69. Recro Pharma had a negative return on equity of 472.52% and a negative net margin of 83.56%. The business had revenue of $25.07 million during the quarter, compared to analysts’ expectations of $20.51 million. Research analysts expect that Recro Pharma will post -0.54 earnings per share for the current fiscal year.
In related news, CEO Geraldine Henwood sold 144,806 shares of the stock in a transaction on Monday, May 13th. The stock was sold at an average price of $8.89, for a total value of $1,287,325.34. Following the completion of the transaction, the chief executive officer now owns 342,947 shares in the company, valued at approximately $3,048,798.83. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Arnaud Ajdler purchased 40,000 shares of the firm’s stock in a transaction that occurred on Friday, May 17th. The stock was bought at an average price of $9.00 per share, with a total value of $360,000.00. The disclosure for this purchase can be found here. Company insiders own 20.10% of the company’s stock.
Several large investors have recently added to or reduced their stakes in REPH. Meeder Asset Management Inc. lifted its stake in Recro Pharma by 191.1% in the 1st quarter. Meeder Asset Management Inc. now owns 5,086 shares of the specialty pharmaceutical company’s stock worth $30,000 after acquiring an additional 3,339 shares in the last quarter. Bessemer Group Inc. purchased a new stake in Recro Pharma in the 2nd quarter worth about $57,000. Truvestments Capital LLC purchased a new stake in Recro Pharma in the 1st quarter worth about $38,000. Virtu Financial LLC lifted its stake in Recro Pharma by 27.7% in the 1st quarter. Virtu Financial LLC now owns 12,875 shares of the specialty pharmaceutical company’s stock worth $75,000 after acquiring an additional 2,795 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in Recro Pharma by 210.4% in the 4th quarter. Bank of America Corp DE now owns 27,182 shares of the specialty pharmaceutical company’s stock worth $193,000 after acquiring an additional 18,424 shares in the last quarter. Institutional investors and hedge funds own 57.19% of the company’s stock.
Recro Pharma Company Profile
Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Read More: What is a Special Dividend?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.